Retatrutide Advantages Highest weight loss ever reported in an obesity drug trial Third receptor adds energy expenditure and fat oxidation Weight loss curve not yet plateaued at 48 weeks Stronger liver fat reduction potential via glucagon pathway 100% of highest-dose participants lost at least 5% body weight Tirzepatide Advantages FDA approved and commercially available (Mounjaro, Zepbound) Large Phase 3 dataset with 10,000+ participants across programs No dose-dependent heart rate increase observed Longer real-world data and post-marketing surveillance Multiple completed trials across obesity and diabetes indications Key Takeaways Retatrutides Phase 2 data shows a small numerical weight loss advantage over tirzepatides Phase 3 data (24.2% vs 22.5%), but the comparison is indirect and the trial designs are not equivalent
Yes, tirzepatide can be injected safely at any time of day, including evening
Does the temperature of the bacteriostatic water matter during mixing
FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk: How to protect and advance the public health through more robust regulatory oversight and timely legislative action
One patient with a history of advanced breast cancer developed sepsis
Eur J Nutr 63(1):6778 Lee JY, Kim WK, Bae KH, Lee SC, Lee EW (2021) Lipid metabolism and ferroptosis
